Prostate Cell News Volume 1.01 | Jan 15 2010

Jewish General Hospital Discovery Opens Door to New Treatments for Prostate, Brain and Skin Cancers
Scientists discovered a novel link between the tumour-suppressing gene PTEN and a protein called PKR, which is known to inhibit protein synthesis. [Jewish General Hospital, Montreal; McGill University, Montreal]

		Optimized Enzymes and Protocols for Prostate Tissue Dissociation by STEMCELL Technologies
		CLICK HERE TO LEARN MORE

Wild East or Scientific Feast?
In the field of stem cells, China is showing that it can do world-class science. It is a shame, then, that so many fraudsters operate and that officialdom turns a blind eye. [The Economist]

Genetic Variant Associated with Aggressive Form of Prostate Cancer
Researchers have identified the first genetic variant associated with aggressive prostate cancer, proving the concept that genetic information may one day be used in combination with other factors to guide treatment decisions. [Wake Forest University, Winston-Salem]

Race, Obesity Affect Outcomes Among Diabetics Following Prostatectomy
Obese white men who have both diabetes and prostate cancer have significantly worse outcomes following radical prostatectomy than do men without diabetes who undergo the same procedure. [Duke University, Durham]

		Detect 7x More Prostate Epithelial Progenitor Cells with ProstaCult™ by STEMCELL Technologies
		CLICK HERE TO LEARN HOW

LABORATORY RESEARCH

Suppression of Human Prostate Tumor Growth by a Unique Prostate-Specific Monoclonal Antibody F77 Targeting a Glycolipid Marker
Scientists have identified a monoclonal antibody that is capable of binding to a cell surface antigen specifically expressed on both androgen-dependent and androgen-independent prostate cancer cells. [PNAS]

Role of DAB2IP in Modulating Epithelial-to-Mesenchymal Transition and Prostate Cancer Metastasis
The loss of DAB2IP expression initiates epithelial-to-mesenchymal transition, which is visualized by repression of E-cadherin and up-regulation of vimentin in both human normal prostate epithelial and prostate carcinoma cells as well as in clinical prostate cancer specimens. [PNAS]

A FOXA1-Binding Enhancer Regulates Hoxb13 Expression in the Prostate Gland
To elucidate the molecular basis of prostate-restricted transcriptional activation of Hoxb13, a bacterial artificial chromosome-based reporter, gene deletion analysis was performed in transgenic mice. [PNAS]

Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression
Coimplantation of phosphoglycerate kinase-1 (PGK1)-overexpressing fibroblasts with prostate tumor cells promoted tumor cell growth in vivo. Collectively, these observations suggest that PGK1 helps support the interactions between cancer and its microenvironment. [Cancer Res]

Down-Regulation of Notch-1 and Jagged-1 Inhibits Prostate Cancer Cell Growth, Migration and Invasion, and Induces Apoptosis Via Inactivation of Akt, mTOR, and NF-kappaB Signaling Pathways
Using multiple cellular and molecular approaches such as MTT assay, apoptosis assay, gene transfection, real-time RT-PCR, Western blotting, migration, invasion assay and ELISA, researchers found that down-regulation of Notch-1 or Jagged-1 was mechanistically associated with inhibition of cell growth, migration, invasion and induction of apoptosis in prostate cancer cells. [J Cell Biochem]

Clusterin Facilitates COMMD1 and I-KappaB Degradation to Enhance NF-KappaB Activity in Prostate Cancer Cells
Researchers propose that elevated levels of Secretory clusterin promote prostate cancer cell survival by facilitating degradation of COMMD1 and I-KappaB, thereby activating the canonical NF-KappaB pathway. [Mol Cancer Res]

The Role of PI 3-Kinase p110Beta in AKT Signaling, Cell Survival, and Proliferation in Human Prostate Cancer Cells
Results support the concept that p110Beta appears to be the predominant functional class I PI 3-kinase isoform in prostate cancer cells. [Prostate]

CLINICAL RESEARCH

Tumor O6-Methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib
Total O6-methylguanine-DNA methyltransferase inactivation can be achieved in prostate, primary central nervous system, and colorectal cancers with a single administration of 120 or 160 mg lomeguatrib. [Clin Cancer Res]

Is Delayed Radical Prostatectomy in Men with Low-Risk Screen-Detected Prostate Cancer Associated with a Higher Risk of Unfavorable Outcomes?
Strategies of active surveillance of low-risk screen-detected prostate cancer have emerged, because the balance between survival outcomes and quality of life issues when radically treating these malignancies is disputable. Delay before radical treatment caused by active surveillance may be associated with an impaired chance of curability. [Cancer]

		Use ALDEFLUOR® to Detect Prostate Precursor Cells by STEMCELL Technologies
		WATCH THE VIDEO

Dendreon Sees Full Provenge Capacity by Mid-2011
Dendreon Corp. expects to reach full manufacturing capacity for experimental prostate cancer drug Provenge by mid-2011, and will immediately launch sales of the drug when it is approved by U.S. regulators.

Theragenics Announces Supply and Reseller Agreement with Core Oncology
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

After Long March, Scientists Create ‘Chinese National Institutes of Health’
The National Natural Science Foundation of China launched a medical department that expects to disburse about 1 billion renminbi ($150 million) in government grants in 2010. [The National Natural Science Foundation of China, People’s Republic of China]

Advisory Committees; Tentative Schedule of Meetings for 2010 [Food and Drug Administration, United States]

NIH Broadens Eligibility for NIH Diversity and Re-Entry Supplements (NOT-OD-10-045) [National Institutes of Health, United States]

Salary Limitation on FY2010 AHRQ Grants, Cooperative Agreements, and Contracts (NOT-HS-10-012) [Agency for Healthcare Research and Quality, United States]

New Iberia Research Center 101 and 201 PLUS Workshops: February 24-25, 2010 in Lafayette, LA (NOT-OD-10-044) [National Institutes of Health, United States]

Ruth L. Kirschstein National Research Service Award Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2010 (NOT-OD-10-047) [National Institutes of Health, United States]

7th Meeting of the EAU Section of Oncological Urology
January 15-17, 2010
Vienna, Austria

Stem Cells and Regenerative Medicine World Congress
January 20-21, 2010
San Francisco, United States

Phacilitate Cell and Gene Therapy Forum 2010
January 25-27, 2010
Washington DC, United States

CHI’s Molecular Medicine Tri-Conference 2010
February 3-5, 2010
San Francisco, United States

AACR/JCA Joint Conference: Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics
February 5-9, 2010
Waikoloa, United States

SMi’s Second Annual Stem Cells 2010
February 15-16, 2010
London, United Kingdom

Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
February 15-20, 2010
Keystone, United States

5th Annual Stem Cell Summit
February 16, 2010
New York, United States

Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
February 24-27, 2010
Washington, DC, United States

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research Annual Meeting
April 17-21, 2010
Washington, DC, United States

JOB OPPORTUNITIES

Business Development Europe – Cell Therapy Products, Germany (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!